Back to Search Start Over

Bigger problems from smaller colonies: emergence of antibiotic-tolerant small colony variants of Mycobacterium avium complex in MAC-pulmonary disease patients.

Authors :
Park, Hyun-Eui
Kim, Kyu-Min
Trinh, Minh Phuong
Yoo, Jung-Wan
Shin, Sung Jae
Shin, Min-Kyoung
Source :
Annals of Clinical Microbiology & Antimicrobials; 3/18/2024, Vol. 23 Issue 1, p1-16, 16p
Publication Year :
2024

Abstract

Background: Mycobacterium avium complex (MAC) is a group of slow-growing mycobacteria that includes Mycobacterium avium and Mycobacterium intracellulare. MAC pulmonary disease (MAC-PD) poses a threat to immunocompromised individuals and those with structural pulmonary diseases worldwide. The standard treatment regimen for MAC-PD includes a macrolide in combination with rifampicin and ethambutol. However, the treatment failure and disease recurrence rates after successful treatment remain high. Results: In the present study, we investigated the unique characteristics of small colony variants (SCVs) isolated from patients with MAC-PD. Furthermore, revertant (RVT) phenotype, emerged from the SCVs after prolonged incubation on 7H10 agar. We observed that SCVs exhibited slower growth rates than wild-type (WT) strains but had higher minimum inhibitory concentrations (MICs) against multiple antibiotics. However, some antibiotics showed low MICs for the WT, SCVs, and RVT phenotypes. Additionally, the genotypes were identical among SCVs, WT, and RVT. Based on the MIC data, we conducted time-kill kinetic experiments using various antibiotic combinations. The response to antibiotics varied among the phenotypes, with RVT being the most susceptible, WT showing intermediate susceptibility, and SCVs displaying the lowest susceptibility. Conclusions: In conclusion, the emergence of the SCVs phenotype represents a survival strategy adopted by MAC to adapt to hostile environments and persist during infection within the host. Additionally, combining the current drugs in the treatment regimen with additional drugs that promote the conversion of SCVs to RVT may offer a promising strategy to improve the clinical outcomes of patients with refractory MAC-PD. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
14760711
Volume :
23
Issue :
1
Database :
Complementary Index
Journal :
Annals of Clinical Microbiology & Antimicrobials
Publication Type :
Academic Journal
Accession number :
176300518
Full Text :
https://doi.org/10.1186/s12941-024-00683-6